Theefficiency of the proposed method was confirmed by the obtaining fluorescentand magnetic nanoparticles modified with DARPin 9_29 recognizing the HER2 tumormarker and by targeted delivery of these nanoparticles to theHER2-overexpressing cancer cells. The gene discussed is ERBB2; the disease is cancer.